Ambulatory Parkinson's Disease Dyskinesia Monitor for Drug Therapy Titration

Great Lakes NeuroTechnologies Inc.14 enrolled

Overview

The objective is to assess a compact, portable, wireless movement disorder system with continuous monitoring capabilities to detect and quantify the severity of levodopa-induced dyskinesia in Parkinson's disease.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Parkinson's Disease

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of idiopathic Parkinson's disease * Clinical history of levodopa-induced dyskinesia * 21 Years of age or older * Stage 2 - 4 OFF-medication on the Hoehn and Yahr scale Exclusion Criteria: * Dementia (determined by a neuropsychological assessment) * Severe tremor unaffected by levodopa

Locations (2)

Johns Hopkins Medical Center

Baltimore, Maryland, United States

University of Rochester Medical Center

Rochester, New York, United States

Outcomes

Primary Outcomes

Correlation between motion sensor features and clinician-rated dyskinesia severity

Motor function (movement speed and magnitude measured with a motion sensor) will be collected for a period of 2 hours after taking normally prescribed dose of levodopa.

Time frame: All data will be collected within a single session not to exceed 3 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.